Skip to main content
. 2009 Nov 27;101(3):646–651. doi: 10.1111/j.1349-7006.2009.01451.x

Figure 4.

Figure 4

 Cancer‐specific survival in patients with prostate cancer according to the immunoreactivity (IR) of estrogen‐related receptor (ERR)‐β and ERRγ (n = 107). No significant difference was observed in ERRβ IR (a), whereas patients with low ERRγ IR tended to show poor cancer‐specific survival (b). The patients with high ERRα IR and low ERRγ IRs (IR score, ≤4) showed significantly poorer cancer‐specific survival than patients with low ERRα IR and high ERRγ IRs and the other patients (P = 0.0003 and 0.07, respectively) (c).